Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:23:23 EDT Thu 17 Jul 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:AGEN from 2024-07-18 to 2025-07-17 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-07-07 08:55U:AGENNews ReleaseAgenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
2025-06-17 07:30U:AGENNews ReleaseAgenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
2025-06-17 07:30U:AGENNews ReleaseAgenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
2025-06-10 13:30U:AGENNews ReleaseAgenus Announces Virtual Annual Shareholders Meeting
2025-06-03 07:00U:AGENNews ReleaseAgenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US
2025-05-30 07:30U:AGENNews ReleaseAgenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer
2025-05-15 10:40U:AGENNews ReleaseAgenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
2025-05-12 07:30U:AGENNews ReleaseAgenus Reports Q1 2025 Financial Results and Key Business Updates
2025-05-12 07:20U:AGENNews ReleaseRenowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
2025-04-29 07:30U:AGENNews ReleaseAgenus to Provide Corporate Update and First Quarter 2025 Financial Report
2025-04-28 15:30U:AGENNews ReleaseAgenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
2025-04-25 13:05U:AGENNews ReleaseAgenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
2025-04-23 12:05U:AGENNews ReleaseAgenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
2025-03-25 16:40U:AGENNews ReleaseAgenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
2025-03-19 07:30U:AGENNews ReleaseAgenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
2025-03-11 07:30U:AGENNews ReleaseAgenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
2025-02-26 16:48U:AGENNews ReleaseAgenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
2025-02-25 14:30U:AGENNews ReleaseAgenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
2025-02-25 08:26U:AGENNews ReleaseAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
2025-02-24 08:33U:AGENNews ReleaseAgenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
2025-02-12 10:00U:AGENNews ReleaseCORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
2025-01-29 12:37U:AGENNews ReleaseAgenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
2025-01-22 14:48U:AGENNews ReleaseAgenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
2024-12-18 07:30U:AGENNews ReleaseAgenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
2024-12-05 07:30U:AGENNews ReleaseAgenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
2024-11-27 08:15U:AGENNews ReleaseAgenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
2024-11-12 07:00U:AGENNews ReleaseAgenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
2024-11-07 10:00U:AGENNews ReleaseAgenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
2024-11-05 07:30U:AGENNews ReleaseAgenus to Provide Third Quarter 2024 Financial Report and Corporate Update
2024-09-13 10:00U:AGENNews ReleaseBotensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
2024-09-09 07:30U:AGENNews ReleaseBotensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
2024-09-03 07:30U:AGENNews ReleaseAgenus to Participate in September Investor Conferences
2024-08-08 07:00U:AGENNews ReleaseAgenus Announces Appointment of Tom Harrison to Board of Directors
2024-08-08 07:00U:AGENNews ReleaseAgenus Reports Second Quarter 2024 Operational and Financial Results
2024-08-07 10:58U:AGENNews ReleaseAgenus Publishes Seminal Study on Botensilimab's Activity in Treatment-Resistant Cancers
2024-07-26 07:00U:AGENNews ReleaseAgenus to Provide Second Quarter 2024 Financial Report and Corporate Update
2024-07-18 07:00U:AGENNews ReleaseAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer